Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term sunitinib. Found 9 abstracts

von Mehren M, Rankin C, Goldblum JR, Demetri GD, Bramwell V, Ryan CW, Borden E. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer. 2012 Feb;118(3):770-6.   PMCID: PMC3576704
Plimack ER, Hudes GR. Selecting Targeted Therapies for Patients With Renal Cell Carcinoma. Journal of the National Comprehensive Cancer Network. 2011 Sep;9(9):997-1007.   PMCID: not NIH funded
Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, Bair AH, Ricart AD, Olszanski AJ, Letrent KJ, Kim S, Rixe O. Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors. Clinical Cancer Research. 2011 Jun;17(11):3841-9.   PMCID: not NIH funded
Motzer RJ, Hudes GR, Ginsberg MS, Baum MS, Harmon CS, Kim ST, Chen I, Redman BG. Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology-Cancer Clinical Trials. 2010 Dec;33(6):614-8.   PMCID: not NIH funded
Reichardt P, Blay JY, von Mehren M. Towards global consensus in the treatment of gastrointestinal stromal tumor. Expert Review of Anticancer Therapy. 2010 Feb;10(2):221-32.   PMCID: PMC347555
Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P, Davey M, Borghaei H, Pink D, Debiec-Rychter M, Cheung W, Bailey SM, Veronese ML, Reichardt A, Fumagalli E, Reichardt P. A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors. Clinical Cancer Research. 2009 Sep;15(18):5910-6.   PMCID: PMC2861356
Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP. Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 2009 Sep;27(27):4462-8.   PMCID: not NIH funded
Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Wilding G. Sunitinib efficacy against advanced renal cell carcinoma. Journal of Urology. 2007 Nov;178(5):1883-7.
von Mehren M. Beyond imatinib: Second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. Clinical Colorectal Cancer. 2006 Nov;6:S30-S34.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term sunitinib

sunitinib bevacizumab endothelial growth-factor inhibitor renal cell antitumor-activity therapy carcinoma tyrosine kinase efficacy interferon-alpha factor receptor National Comprehensive Cancer active chemotherapy double-blind KIT mutation tyrosine kinase inhibitor phase-ii trial TYROSINE KINASE INHIBITOR pathology THERAPY trial kidney imatinib Carcinoma dose imatinib stromal tumor 2010 dermott df-v28 liposarcoma GROWTH-FACTOR renal-cell cancer kit mutations grade biology BCR-ABL metaanalysis erlotinib arterial-hypertension AMN107 renal cell carcinoma guidelines genetics MESYLATE IM leiomyosarcoma RAD001 beta-subunit residual disease placebo solitary fibrous tumor growth-factor receptor gefitinib gastrointestinal medullary phase-ii clinical benefit tumors Network IN-VITRO neoplasm metastasis trials ACQUIRED-RESISTANCE prognostic-factors nilotinib acquired-resistance SU11248 imatinib mesylate randomized-trial CHRONIC MYELOID-LEUKEMIA clear cell renal cell carcinoma cancer expression non-clear cell renal cell carcinoma leukemia ENDOTHELIAL GROWTH-FACTOR kinase solid tumors AMG 706 disease gist phase-iii trial hemangiopericytoma European Society of Medical Oncology collecting duct carcinoma PDGFR-alpha BONE-SARCOMA-GROUP angiosarcoma kinase inhibitors kit INTERFERON-ALPHA antiangiogenesis KIT mesylate metastatic SURVIVAL association adjuvant CANCER INHIBITOR pharmacokinetics sarcoma amn107 tyrosine-kinase clinical-trials surgical-management EORTC-SOFT-TISSUE RANDOMIZED-TRIAL PATIENTS PTS kidney neoplasms
Last updated on Friday, January 03, 2020